This is approximately $13.6bn, plus the assumption of net debt at close ($2.2bn as of year-end 2012).
The transaction, approved by both companies’ boards of directors, will create an unrivalled leader in serving research, specialty diagnostics and applied markets.
The combination builds on both companies’ technological strengths to accelerate results for life sciences customers working in proteomics, genomics and cell biology.
It is expected that Life Technologies’ president and chief operating officer, Mark P Stevenson, will have a significant leadership role in the combined company.
In addition, Thermo Fisher intends to elect a member of the Life Technologies board of directors to the Thermo Fisher board.
© FoodBev Media Ltd 2024